Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

favicon.ico

favicon-16x16.png

favicon-32x32.png

apple-touch-icon.png

MoFo Favicons

Terms / Notices

Cookies

Privacy Policy

Attorney Advertising

Secure Login

Alumni

  Facebook

MoFo Facebook

  Linkedin

MoFo LinkedIN

Twitter

MoFo Twitter

YouTube

MoFo Youtube

Morrison Foerster - Footer

You have not solved the recaptcha challenge yet or session expired, try again.

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

Morrison & Foerster LLP advised Hangzhou DAC Biotechnology Co., Ltd. (“DAC Biotechnology”) on its collaboration and license agreement with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the development and commercialization of antibody drug conjugate (ADC) products.



MoFo Advised Hangzhou DAC Biotechnology on Collaboration and License Agreement with Janssen

About Morrison Forester

people-default-header-desktop.jpg

people-default-header-mobile.jpg

Default Meta Data

Morrison & Foerster LLP advised Hangzhou DAC Biotechnology Co., Ltd. (“DAC Biotechnology”) on its collaboration and license agreement with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the development and commercialization of antibody drug conjugate (ADC) products.Under the terms of the agreement, DAC Biotechnology will apply its innovative and proprietary ADC platform to Janssen’s proprietary antibodies with the aim to develop novel ADC products against up to five targets.DAC Biotechnology’s technology concerning payload/linker pairs and conjugation licensed to Janssen is a key component of ADC products. Through the collaboration, DAC Biotechnology will fully leverage its intellectual properties and proprietary ADC platform while Janssen will provide its expertise in proprietary antibodies, clinical development and global commercialization, creating a new approach to progressing novel therapeutic innovations in overseas markets.The MoFo team advising DAC Biotechnology was led by Shanghai TTG/Corporate Partner Chuan Sun, together with Shanghai TTG associate Sarah Wang.

MoFo Advised Hangzhou DAC Biotechnology on Collaboration and License Agreement with Janssen